Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.31 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.31 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221733 | 0.84 | ALDH1A1 (0.36) | KIF11TSHRALDH1A1CES2CES1 | |
| SCHEMBL227931 | 0.84 | TSHR (0.40) | KIF11TSHRALDH1A1LMNATYR | |
| SCHEMBL192799 | 0.73 | ALDH1A1 (0.35) | KIF11TSHRALDH1A1CES2CES1 | |
| SCHEMBL16166891 | 0.73 | ACHE (0.31) | — | |
| SCHEMBL29058847 | 0.72 | KIF11 (0.47) | KIF11TSHRALDH1A1LMNATYR | |
| SCHEMBL28266024 | 0.70 | — | — | |
| SCHEMBL60519 | 0.70 | ALDH1A1 (0.36) | KIF11TSHRALDH1A1CES2CES1 | |
| SCHEMBL956938 | 0.70 | TSHR (0.40) | TSHR | |
| SCHEMBL5115414 | 0.69 | CCNE2 (0.36) | KIF11TRPV1 | |
| SCHEMBL17046271 | 0.69 | TRPV1 (0.36) | KIF11TRPV1TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190161514-A1 | AZASTEROIDS FOR TREATMENT OF TUBERCULOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-05-30 | — | — | US | claimed |
| WO-2017190034-A1 | AZASTEROIDS FOR TREATMENT OF TUBERCULOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-11-02 | — | — | WO | claimed |
| US-20110172258-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | claimed |
| CN-102001916-A | Indene derivatives as pharmaceutical agents | — | 2011-04-06 | — | — | CN | claimed |
| EP-1615866-B1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC (CA) | 2011-02-16 | — | — | EP | claimed |
| US-20100152220-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | claimed |
| CN-1805915-A | Indene derivatives as pharmaceutically active agents | INFLAZYME PHARM LTD (CA) | 2006-07-19 | — | — | CN | claimed |
| US-20050004086-A1 | Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2005-01-06 | — | — | US | claimed |
| EP-0785943-A1 | SYNTHESIS OF 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1997-07-30 | — | — | EP | claimed |
| US-5541322-A | Synthesis of 6-azaandrostenones | GLAXO WELLCOME INC. (US) | 1996-07-30 | — | — | US | claimed |
| WO-1996011939-A1 | SYNTHESIS OF 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1996-04-25 | — | — | WO | claimed |
| US-11072633-B2 | Azasteroids for treatment of tuberculosis | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-07-27 | — | — | US | disclosed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-20190161514-A1 | AZASTEROIDS FOR TREATMENT OF TUBERCULOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-05-30 | — | — | US | disclosed |
| CN-109790200-A | For treating the azasteroid of tuberculosis | 纽约州立大学研究基金会 | 2019-05-21 | — | — | CN | disclosed |
| US-20110009439-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-01-13 | — | — | US | disclosed |
| US-20100152220-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | disclosed |
| US-7601874-B2 | Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease | AQUINOX PHARMACEUTICALS INC. (CA) | 2009-10-13 | — | — | US | disclosed |
| CN-1805915-A | Indene derivatives as pharmaceutically active agents | INFLAZYME PHARM LTD (CA) | 2006-07-19 | — | — | CN | disclosed |
| US-20050004086-A1 | Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161514-A1 | AZASTEROIDS FOR TREATMENT OF TUBERCULOSIS | CYP51A1, HSD17B13, HSD17B1 | KIF11 2861/4885TRPV1 4603/4885TSHR 914/4885 |
| US-11072633-B2 | Azasteroids for treatment of tuberculosis | CYP51A1, HSD17B13, HSD17B1 | KIF11 2861/4885TRPV1 4603/4885TSHR 914/4885 |
| US-20110009439-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSR, INSRR, F12 | KIF11 2640/4885TRPV1 1744/4885TSHR 988/4885 |
| US-20100152220-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSR, INSRR, F12 | KIF11 2569/4885TRPV1 1783/4885TSHR 998/4885 |
| US-20110172258-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSR, INSRR, F12 | KIF11 2569/4885TRPV1 1783/4885TSHR 998/4885 |
| US-20050004086-A1 | Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease | IDO1, URB2, ARG1 | KIF11 4124/4885TRPV1 1257/4885TSHR 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.